This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Greatbatch Announces The Acquisition Of NeuroNexus

Greatbatch, Inc., (NYSE:GB) today announced the acquisition of NeuroNexus Technologies (“NeuroNexus”) for approximately $12 million in cash, including the assumption of debt and future considerations.

NeuroNexus, headquartered in Ann Arbor, Michigan, is an active implantable medical device design firm specializing in developing and commercializing high-value neural interface technology, components and systems for neuroscience and clinical markets. The company has an extensive intellectual property portfolio, core technologies and capabilities to support the development and manufacturing of innovative neural interface devices across a wide range of functions including neuromodulation, sensing, optical stimulation and targeted drug delivery applications.

“We are very excited to have the NeuroNexus team join the QiG Group and Greatbatch family of companies. Together, we believe that we can research, design, develop and manufacture new world-class proprietary products and systems that will expand and potentially re-define the fields of cardiovascular and neuromodulation as we know them today,” stated Thomas J. Hook, President and CEO of Greatbatch, Inc. “Additionally, the strong alliance NeuroNexus has with the University of Michigan and the Michigan Economic Development Corporation should position us to expand our operations in the region.”

Daryl R. Kipke PhD., NeuroNexus President and CEO, stated, “We are delighted to have this opportunity to strengthen and accelerate our position as a world-class leader in neural interface devices. Our innovative, high fidelity and high precision lead technologies combined with QiG Group and Greatbatch capabilities will ensure the achievement of our goals of advancing cardiovascular and neuromodulation clinical therapies and providing innovative research products to leading neuroscientists around the world to fuel progress in neuroscience. Additionally, we are excited that this opportunity allows us to continue and expand our presence in the high-technology hub of Ann Arbor and the broader Michigan region.”

NeuroNexus, founded in 2004, employs approximately 25 associates in its Ann Arbor facility. The highly talented team, many of whom possess advanced doctorate degrees in engineering and neuroscience, have diverse capabilities in medical device development. “The world class team further strengthens our QiG Group’s research, development and engineering talent and expands our footprint in key strategic locations,” Hook concluded.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,083.80 -2.83 -0.02%
S&P 500 1,987.98 +0.97 0.05%
NASDAQ 4,472.1080 -1.5890 -0.04%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs